Drug Name: Filspari
Indications: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.
Active Ingredient: Sparsentan
Company: Travere Therapeutics, Inc
Approval Date: 2/17/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf